Full metadata record
DC FieldValueLanguage
dc.contributor.authorLin, Jun-Songen_US
dc.contributor.authorChiu, Yi-Hanen_US
dc.contributor.authorLin, Nien-Tsungen_US
dc.contributor.authorChu, Chia-Hsiangen_US
dc.contributor.authorHuang, Kuo-Chinen_US
dc.contributor.authorLiao, Kuang-Wenen_US
dc.contributor.authorPeng, Kou-Chengen_US
dc.date.accessioned2014-12-08T15:10:00Z-
dc.date.available2014-12-08T15:10:00Z-
dc.date.issued2009-02-11en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.vaccine.2008.11.114en_US
dc.identifier.urihttp://hdl.handle.net/11536/7636-
dc.description.abstractTreatment and prevention of pediatric infectious diseases of three commercial probiotic products were evaluated by a double-blind, randomized, controlled trial. Test subjects under age 5,1062 in total, were distributed randomly into four groups. This investigation showed that L. casei rhamnosus can control bacterial, viral and respiratory infections; a multi-species probiotic reduced gastrointestinal disease significantly. Long-term consumption of L. rhamnosus T cell-1 decreased the incidence of bacterial infection. (C) 2008 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectProbioticsen_US
dc.subjectPreschooleren_US
dc.subjectInfectionsen_US
dc.titleDifferent effects of probiotic species/strains on infections in preschool children: A double-blind, randomized, controlled studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.vaccine.2008.11.114en_US
dc.identifier.journalVACCINEen_US
dc.citation.volume27en_US
dc.citation.issue7en_US
dc.citation.spage1073en_US
dc.citation.epage1079en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000263712100017-
dc.citation.woscount25-
Appears in Collections:Articles


Files in This Item:

  1. 000263712100017.pdf

If it is a zip file, please download the file and unzip it, then open index.html in a browser to view the full text content.